Valoctocogene Roxaparvovec Gene Therapy Success Detailed For Hemophilia A Patients Overview Valoctocogene roxaparvovec is a gene therapy utilizing an adeno-associated virus serotype 5 (AAV5) vector, approved for treating severe hemophilia A (HA). The purpose of this summary is to present the safety and efficacy outcomes observed seven years post-dosing in a phase
Tag: hemophilia A
